The diagnostic framework for Alzheimer’s Disease is shifting rapidly. With the emergence of high-performance blood-based biomarkers, the journey from clinical suspicion to definitive diagnosis is becoming more precise and accessible.
We are pleased to share with you the webinar recording from June 23rd, 2026, with you and your neurology colleagues focusing on the role of biomarkers, featuring first-hand insights from the team at UZ Gent from their in-house study and 6 months experience with pTau217 plasma.
Elecsys pTau217 plasma recently received CE-marking to detect amyloid pathology - a hallmark of Alzheimer’s disease - in people presenting with cognitive decline. Its clinical utility is backed by robust evidence demonstrating high diagnostic accuracy.
Leave your details below and get direct access to the webinar recording.